|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 培美曲塞联合顺铂治疗晚期肺腺癌的临床分析显示文摘目的评价培美曲塞联合顺铂治疗晚期肺腺癌的疗效和毒副反应。方法 35例经病理或细胞学确诊的晚期肺腺癌初治患者,采用培美曲塞500mg/m2,第1天给药,并口服地塞米松、叶酸和肌内注射维生素B12预处理;顺铂75mg/m2,静滴,分2~4d给药,均予以保肝、护胃、止吐药物。治疗21d为1个周期,2个周期后评价疗效、毒副反应。结果 35例患者中,客观有效率为29%,疾病控制率为69%,PFS8个月(2~12个月),中位总生存期9个月(3~19个月)。毒副反应主要是骨髓抑制、胃肠道反应,均未达到Ⅲ~Ⅳ度。结论培美曲塞联合顺铂一线治疗晚期肺腺癌疗效较好,毒性反应轻,值得临床推广应用。 | 李青 张良明 | 2011 | 中国医药科学2011，1，20： | 1 |
| 2 | 舒尼替尼治疗非小细胞肺癌的现状(英文)显示文摘Sunitinib malate is one of the multitargeted tyrosine kinase inhibitor,which are being used in clinic.It can inhibit more than 80 kinds of receptor`s tyrosine kinase,including epidermal growth factor receptor (EGFR),platelet-derived growth factor receptors,vascular endothelial growth factor receptors (VEGFR),etc.And tyrosine kinase inhibitor is involved in connection with the generation and progression of many kinds of cancer including lung cancer.Several studies have evaluated the effect of Sunitinib on non-small cell lung cancer (NSCLC),by single agent,continuous daily dosing or in combination with chemotherapeutics (with docetaxel or gemcitabine plus cisplatin),which all showed certain effect.The test of Sunitinib in combination with gemcitabine plus cisplatin for advanced NSCLC shown that at the maximum tolerated dose:oral Sunitinib 37.5 mg/day intermittently (Schedule 2/1:2 weeks on treatment,1 week off treatment) schedule with intravenous infusions of gemcitabine (1000 mg/m2 days 1,8) and cisplatin (80 mg/m2 day 1),administered in 3-week cycles,66.7% patients achieved partial responses.And adverse effects were mild to moderate in severity (grades 1 to 2).Therapy was generally well tolerated.In summary,all the evidence above suggests that Sunitinib may play an important role in the treating of NSCLC. | Qingjie Yang Xiaoyan Sun Ming Guo | 2012 | The Chinese-German Journal of Clinical Oncology2012，11，3： | 1 |
| 3 | 金水鲜联合放疗对肺腺癌A549细胞增殖及VEGF表达的影响(英文)显示文摘Objective:The aim of our study was to investigate whether Jinshuixian has the abilities of inhibiting tumor growth and radio-sensitivity effect.Methods:Cultured lung A549 cells were randomly divided into 6 groups:normal control group(NC),the Jinshuixian group(JSX),radiotherapy(RT),JSX for the first day and the next day followed by RT group(JSX→RT),RT for the first day and the next day followed by JSX group(RT→JSX)and RT+JSX concomitantly group(JSX+RT).MTT was applied to measure the cell viability,RT-PCR and ELISA were used to test the expression of mRNA and protein of VEGF.Results:The proliferation of A549 cells were inhibited in JSX and combined groups and the inhibiting effects were time dependent.The expression of VEGF in RT group was increased,however,VEGF in JSX and combination groups were largely decreased over time when compared to NC group.Results in JSX→RT,RT→JSX and JSX+RT groups did not achieve significantly differences.Conclusion:JSX has the ability of anti-tumor growth in vitro accompanied down-regulating of VEGF,especially when combined with radiotherapy,and its effect is time-dependent.However,more studies in vivo and in vitro are needed to further supporting these effects. | Huilin Xu Wei Ge Pingpo Ming Liang Liu Dedong Cao Changhu Li Wei Luo Jing Song | 2013 | The Chinese-German Journal of Clinical Oncology2013，12，9： | 0 |
| 4 | 培美曲塞联合放疗对肺损伤的实验研究(英文)显示文摘Objective: The aim of our study was to examine whether irradiation combined with pemetrexed can exacerbate pulmonary injury. Methods: Two groups of male Wister Rats were subjected to bilateral apex of lungs irradiation(a single dose of 12 Gy), with or without pemetrexed(20 mg/kg) by intraperitoneal injection at the same time; a third group of weightand age- matched animals were treated with pemetrexed alone, as the same dose scheme, time and root of injection. The fourth group served as control. The whole lung mounts were dissected to histological evaluation, while serum cytokine transforming growth factor-β1(TGF-β1) analysis were compared at 1, 7, 21, 35, 49 days post-irradiation after irradiation. Results: Histological examination showed a thickening of alveolar septal, accumulation of inflammatory cells. The irradiation treatment group and the radiation-chemo treatment group showed a statistically significant higher level of TGF-β1(P < 0.05) than other two groups, but there were no differences between these two irradiation groups. Conclusion: These results demonstrated that pemetrexed can not aggravate pulmonary injury and it could be safely used in concurrent or sequential radio-chemotherapy in lung adenocarcinoma. | Qi Qi Yongheng An Hongsheng Yu Haijun Lu Haiji Wang | 2014 | The Chinese-German Journal of Clinical Oncology2014，13，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员